Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening

Eur J Med Chem. 2016 Oct 21:122:429-435. doi: 10.1016/j.ejmech.2016.06.048. Epub 2016 Jun 29.

Abstract

Ataluren, also known as PTC124, is a 5-(fluorophenyl)-1,2,4-oxadiazolyl-benzoic acid suggested to suppress nonsense mutations by readthrough of premature stop codons in the mRNA. Potential interaction of PTC124 with mRNA has been recently studied by molecular dynamics simulations highlighting the importance of H-bonding and stacking π-π interactions. A series of non-acidic analogues of PTC124 were selected from a large database via a ligand-based virtual screening approach. Eight of them were synthesized and tested for their readthrough activity using the Fluc reporter harboring the UGA premature stop codon. The most active compound was further tested for suppression of the UGA nonsense mutation in the bronchial epithelial IB3.1 cell line carrying the W1282X mutation in the CFTR gene.

Keywords: CFTR gene; Cystic fibrosis; Nonsense mutation; Oxadiazoles; PTCs readthrough.

MeSH terms

  • Codon, Nonsense / drug effects*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Drug Evaluation, Preclinical
  • HeLa Cells
  • Humans
  • Molecular Conformation
  • Molecular Dynamics Simulation
  • Oxadiazoles / chemistry
  • Oxadiazoles / metabolism
  • Oxadiazoles / pharmacology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism

Substances

  • Codon, Nonsense
  • Oxadiazoles
  • RNA, Messenger
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • ataluren